A. Lynam* **, M. Quinlan**, S. Clarke* **, L. Pomeroy**, M. Kelleher***, B. Crowley***, F. Cooney****, F. Lyons* on behalf of the Gonorrhoea control group.

Slides:



Advertisements
Similar presentations
John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Evaluation of the.
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
An introduction to sexual health screening for Health Care Assistants
Antimicrobial Resistance in N. gonorrhoeae A Review
Antimicrobial Resistance in N. gonorrhoeae – An Overview 2014 INTRODUCTION Progressive antimicrobial resistance in Neisseria gonorrhoeae is an emerging.
Social aspects of chain of evidence Dr Jan Welch King’s College Hospital.
CDC National Infertility Prevention Project Laboratory Update Region I Wells Beach, Maine June 1-3, 2009 Richard Steece, Ph.D., D(ABMM)
Antimicrobial Resistance in N. gonorrhoeae: In Brief 2014 INTRODUCTION Increased action is needed to help prevent and control gonorrhea. Worldwide antimicrobial.
National Chlamydia Screening Programme Chlamydia testing and diagnoses in year olds, England January – December 2013 CTAD Team HIV & STI Department.
Molecular testing for Neisseria gonorrhoeae J.Dave.
DC American Academy of Pediatrics Adolescent Health Working Group Expedited Partner Therapy Fact Sheet Updated February 20, 2014 DC American Academy of.
2014 PATIENT HISTORY How would you diagnose and screen Miranda? How would you treat Miranda? Are there any additional steps you would take? Antimicrobial.
National Audit Group UK National Audit of Chlamydial Infection Management National Audit Group British Association for Sexual Health & HIV.
Trevor Winstanley Rebecca Clarke Department of Microbiology
Gonorrhea in New York City Epidemiology, Disease Control Activities, and Challenges Presented by: Julia A. Schillinger, MD, MSc CAPT USPHS Bureau of STD.
Sexually Transmitted Infections: UK National Screening and Testing Guidelines BASHH Guidelines 2006 Dr Olwen Williams.
Region I Laboratory Update CDC National Infertility Prevention Project Boston, Massachusetts November 15, 2010 Richard Steece, Ph.D., D(ABMM) Laboratory.
Gonorrhea Increases In Washington State: Gonorrhea Increases In Washington State: Analyses for intervention planning May 2011 Mark R. Stenger Infectious.
STDs among Men who Have Sex with Men (MSM), San Francisco 2007—2010 STD Prevention and Control Services San Francisco Department of Public Health.
The Impact of Introducing “Express Visits” for Asymptomatic Persons Seeking STD Services in a Busy Urban STD Clinic System, Borrelli J 1, Paneth-Pollak.
Validity of Polymerase Chain Reaction Using Liquid Transport Media During a Pertussis Outbreak Cynthia Schulte, RN, BSN VPD Surveillance Officer Bureau.
SSuN Cycle 2 SSuN Part B Laboratory Component: Trichomonas Resistance Evaluation Bob Kirkcaldy, Lori Newman, Kristen Mahle December 4, 2008.
Region II Infertility Prevention Project December New York City, New York Steven J. Shapiro Infertility Prevention Project Coordinator CDC/CCID/NCHHSTP/DSTDP/PTB.
Infectious Disease Epidemiology, Module I Introduction.
Gonorrhea in San Francisco Kyle T Bernstein Chief, Epidemiology, Research and Surveillance STD Prevention and Control Services San Francisco Department.
Evaluation of Presumptive Treatment Recommendation for Asymptomatic Anorectal Gonorrhoea and Chlamydia Infections in At-Risk Kenyan MSM IAS 24 July 2012.
WHEN DID THE NEW VARIANT OF CHLAMYDIA TRACHOMATIS (nvCT) EMERGE IN ÖREBRO COUNTY, SWEDEN? – A STATISTICAL EVALUATION OF THE POSITIVITY RATES FROM 1999.
A Universal Testing Programme for Blood Borne Viruses in an Urban Emergency Department – a call for widespread ED testing in Ireland S O’Connell 1, D Lillis.
Critical Care Department St. Michael’s Hospital Research Program © 2003 Critical Care Dept, St. Michael’s Hospital.
Trends in Neisseria gonorrhoeae Incidence in Washington State Region X GC Meeting Trends in Neisseria gonorrhoeae Incidence in Washington State Region.
The Picture regarding STIs in the Republic of Ireland Dr. Aidan O’Hora Health Protection Surveillance Centre Dublin CAWT April 27 th 2012.
Outbreak of Lymphogranuloma Venereum (LGV) in the greater Dublin area Presentation at SSSTDI meeting 29 th November 2014 Dr. Fionnuala Cooney Chair LGV.
Prevalence of Chlamydia and Gonorrhea Among Patients With Genital Ulcer Disease in Zimbabwe: Potential Implications for Syndromic Management More Mungati:
Review of Gonorrhoea (GC) Contacts Gay Men’s Health Service 2012 / 2013 Louise PomeroyMick QuinlanSusan Clarke GMHSGMHSSJH / GMHS 9 th November 2013.
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
STI Management- When to refer? Dr Vendela McNamara Leicester Sexual Health Service.
For 2010/ schools 58,000 girls 1st and 2nd year special schools home schooled May cohort September cohort Blitz and mop up An Audit of Discharges.
BASHH Conference – Oxford 2016 Whole genome sequencing to predict Neisseria gonorrhoeae antibiotic susceptibility: toward tailored antimicrobial therapy.
Self-taken extragenital samples compared with clinician-taken extragenital samples for the diagnosis of gonorrhoea and chlamydia in women and MSM Janet.
Human Immunodeficiency Virus Infection among Patients with Sexually Transmitted Infections in Zimbabwe: More Mungati: MBChB, MPH Zimbabwe Ministry.
Gabriella Bathgate, Melissa Perry, John White
R ATES OF A SYMPTOMATIC L YMPHOGRANULOMA V ENEREUM IN MEN WHO HAVE SEX WITH MEN Tristan Griffiths Neesha Rockwood Nneka Nwokolo 56 Dean Street, Chelsea.
CHLAMYDIA TRACHOMATIS – DIAGNOSIS AND MANAGEMENT Jess Gaddie (adapted from presentation by Rachel Coyne)
100% Ciprofloxacin resistance in gonococcal isolates in patients with or at high risk of HIV acquisition in an urban Ugandan clinic DR EMILY MABONGA KING’S.
Risk Behaviour, Health Care Access and Prevalence of infection with Chlamydia trachomatis and Neisseria gonorrhoea in a population based sample of.
What’s New in STI Testing?
Gonorrhea Testing, Diagnosis and Treatment
Extra-genital samples for gonorrhoea and chlamydia in women and MSM Self-taken samples analysed separately compared with self-taken pooled samples Janet.
Vaginal Swabs Clinical Information Why? Murray Robinson
Hepatitis C in MSMs; a review of testing practices in the GUIDe clinic & a description of recent cases N. Lynn*, J Dean**, e quinn**, G Farrell*, C Murray*
Rectal chlamydia infection in women Have we been missing the point?
Gill Bell, Nurse Consultant Sexual health Adviser, Sheffield
Implementing a test and treat pathway for Mycoplasma Genitalium (MG) in men with Non-Specific Urethritis (NSU) attending a GUM clinic John Reynolds-Wright1,
Mycoplasma genitalium and macrolide resistance in pelvic inflammatory disease (PID) Gillian Dean1, Jennifer Whetham1, Suneeta Soni1, Rachel Pitt2, Sarah.
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
and for minimising the impact of antimicrobial resistance in
Topic Gonorrhea Diseases
A qPCR assay that simultaneously detects Mycoplasma genitalium and mutations associated with macrolide resistance Litty Tan Director of Research & Development.
SSSTDI Autumn Meeting 25th Nov 2016
An outbreak of high level azithromycin resistant gonorrhoea in Leeds Actions taken by the clinical team and lessons learnt Jane Brown, Health Advisor,
Richard Steece, Ph.D., D(ABMM)
Do Patients adherent on PrEP exposed to HIV have seroconversion symptoms & falsely reactive HIV tests? Mark Roche1, Elaney Youssef1, Yvonne Gilleece¹,
A decade of multi-drug resistant N. gonorrhoea in Coventry, UK
Gonorrhoea antimicrobial resistance in Ireland, 2010 – 2017 On behalf of the National Forum on Antimicrobial Resistance in Neisseria gonorrhoeae Health.
Understanding the increase in gonorrhoea diagnoses from GUM clinics (Northern Ireland) S Todd 1, S McGuinness 2, N Irvine 2, S Quah 1 1 Public Health.
Management of Gonorrhea and Chlamydia in Patients with HIV
Sexually Transmitted Infections (STIs) in Ireland, 2016
M Javanbakht, S Guerry, LV Smith, P Kerndt
HIV, STIs and Hepatitis among men who have sex with men (MSM) in Ireland October provisional data.
Nucleic Acid Amplification Tests for the Diagnosis of Chlamydia trachomatis Rectal Infections Bachmann LH1,2, Johnson R3, Cheng H1, Markowitz L3, Papp.
Presentation transcript:

A. Lynam* **, M. Quinlan**, S. Clarke* **, L. Pomeroy**, M. Kelleher***, B. Crowley***, F. Cooney****, F. Lyons* on behalf of the Gonorrhoea control group *Department of Genitourinary Medicine and Infectious Diseases, St. James’s Hospital, Dublin 8 **Gay Men’s Health Project, Baggott Street Hospital, Dublin 2 ***Department of Microbiology, Clinical Pathology Laboratory, St. James’s Hospital, Dublin 8 **** Dept. of Public Health, HSE East, Dr Steevens’ Hospital, Dublin 8.

Introduction A gonorrhoea control group was convened by Public Health, HSE East in December 2012 in response to an increase in reported cases

Introduction Enhanced surveillance of cases Q1 2013, increased awareness amongst HCPs and public awareness campaign

Introduction A significant proportion of reported cases had positive gonorrhoea NAAT from the pharyngeal site only Patients rarely report pharyngeal symptoms

Introduction – GC diagnostics Abbott Real-Time CT/NG PCR System introduced in September 2010 Target: Multiplex PCR for C. trachomatis targeting 2 x Cryptic plasmid DNA + Pumpkin gene (IC) +/-N. gonorrhoeae opacity (Opa) gene All reactive samples are confirmed on an in house PCR – por A, sufficiently divergent* *In line with BASHH guidelines

Introduction – GC diagnostics Prior to September 2010, routinely used GC culture  Very sensitive to drying Use a transport medium  Fastidious organism Selective media New York City media or chocolate with antibiotic supplement blood/serum, growth factors (iron, haemin, coenzyme NAD) Warm plates before inoculation Capnophilic: prefer increased levels CO 2 (5-10%), 35-37°C Sensitivity: up to 85%

Culture positive obviously replicating organisms – are NAAT positive samples representative of replicating organisms?

Objectives Determine the spontaneous clearance (as determined by NAAT) of pharyngeal GC in patients with positive GC NAAT at pharyngeal site only Determine the proportion of pharyngeal GC positive NAATs that are culture positive Examine factors associated with clearance/persistence

Methods In line with current guidelines all patients with positive GC NAAT are recalled for GC culture from site of positive NAAT Treatment (ceftriaxone 500mg IM + azithromycin PO*) Partner notification Arrangements made for test of cure Between April and September 2014, individuals with a positive NAAT at pharyngeal only site Usual care Repeat NAAT and culture taken at time of recall, prior to treatment *azithromycin at 1 or 2g PO

Results April to September individuals were identified Initial screen gonorrhoea positive at pharyngeal site only AND A second screen was taken prior to treatment All Male Asymptomatic screens Median age 28 years (range years) 58/63(82.1%) HIV negative

Results *not applicable 1 st screen2 nd screen NAAT culture Positive6340/4928/63 NegativeNA*9/4935/63 Not performed NA*140 Culture positive in 28/63 22 NAAT positive 6 did not have NAAT repeated NAAT negative 9/49 All culture negative

Results Second screen NAAT positive 40/49(82%), 95% CI NAAT negative 9/49 (18%), 95% CI Culture positive 28/63(44%), 95% CI Culture negative 35/63(56%), 95% CI

Results Median time between screens (days): 7 (range 5 – 33) NAAT negative/culture negative (7, 7-23) NAAT positive/culture negative (7, 5-15) NAAT positive/culture positive (7, 7-27)

Conclusion In this small study 18% individuals were negative on repeat NAAT prior to treatment 56% individuals were culture negative prior to treatment Further work is needed to better understand the clinical significance of positive GC NAAT when found at the pharyngeal site only